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Human Papilloma Virus (HPV)-positive head and neck
squamous cell carcinoma (HNSCC) is clinically distinct
from HPV-negative HNSCC, and as such requires differ-
ential therapeutic approaches. Accumulating evidence
indicates a significant linkage between the immune
response within the tissue and pathogenesis of HPV-
associated HNSCC. To further elucidate immune-related
signatures in HPV-associated HNSCC, we performed
multiplex histological analysis in de-identified tissue
microarray sections including HPV-positive (n = 21),
HPV-negative (n = 17), and normal oropharynx (n = 8).
Following immunohistochemistry (IHC) for CD45, CD3,
CD8, Foxp3, T-bet, GATA-3, RORgT, CD20, CD56,
CD68, MHC class II, CSF1R, CD66b, tryptase, CD83,
DC-SIGN, PD-1, and PD-L1, the cell intensity per mm2
ratio/composition, localization were quantitatively evalu-
ated. The HPV-status was confirmed by HPV16/18 poly-
merase chain reaction and IHC for p16INK4a. IHC for
p16 or EpCAM were utilized for defining tumor region.
Infiltration of T cell populations including CD45+CD3
+CD8+ T cells (P < 0.01), CD45+CD3+CD8−Foxp3+ regula-
tory T cells (P < 0.05) and CD45+CD3+CD8−Foxp3+T-
bet+ Th1 cells (P < 0.01), CD45+CD20+CD3−B cells (P <
0.05), CD45+CD68+CD163− macrophages (P < 0.001), and
CD45+Tryptase+ mast cells (P < 0.01) was significantly
higher in the HPV-positive group than in the HPV-negative
group. CD8/CD68 ratio of HPV-positive tumor was higher
than that of HPV-negative tumor (P < 0.05), and the high-
est CD163−CD68+/CD163+CD68+ ratio was observed in
the intra-tumor region of HPV-positive tumors. High
PD-L1 expression on CD68+CD163+ macrophages and
MHC class II+CD83+ dendritic cells was intensively
observed in the intra-tumor region of the HPV-positive
group while maturation of dendritic cells assessed by
CD83/DC-SIGN ratio was significantly higher in the
peritumoral stroma than intra-tumor regions (P < 0.05),
indicating distinct immune regulatory mechanisms
between intra and peritumoral regions. These signatures
provide further evidence of anti-tumor immunity
against HPV-positive head and neck cancer, and poten-
tially lead to personalized treatment including immuno-
modulatory therapeutic targets specialized for the HPV/
immune status.
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